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Magnolin targeting of ERK1/2 inhibits cell proliferation and
colony growth by induction of cellular senescence in ovarian
cancer cells
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Ras/Raf/MEKs/ERKs and PI3 K/Akt/mTOR signaling pathways have key roles in cancer
development and growth processes, as well as in cancer malignance and chemoresistance. In this study, we screened the therapeutic potential of magnolin using 15
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human cancer cell lines and combined magnolin sensitivity with the CCLE mutaome
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SKOV3 cells by G1 and G2/M cell cycle phase accumulation. Notably, magnolin
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analysis for relevant mutation information. The results showed that magnolin efficacy
on cell proliferation inhibition were lower in TOV-112D ovarian cancer cells than that in
suppressed colony growth of TOV-112D cells in soft agar, whereas colony growth of
SKOV3 cells in soft agar was not affected by magnolin treatment. Interestingly,
phospho-protein profiles in the MAPK and PI3 K signaling pathways indicated that
SKOV3 cells showed marked increase of Akt phosphorylation at Thr308 and Ser473 and
very weak ERK1/2 phosphorylation levels by EGF stimulation. The phospho-protein
profiles in TOV-112D cells were the opposite of those of SKOV3 cells. Importantly,
magnolin treatment suppressed phosphorylation of RSKs in TOV-112D, but not in
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SKOV3 cells. Moreover, magnolin increased SA-β-galactosidase-positive cells in a dosedependent manner in TOV-112D cells, but not in SKOV3 cells. Notably, oral
administration of Shin-Yi fraction 1, which contained magnolin approximately 53%,
suppressed TOV-112D cell growth in athymic nude mice by induction of p16Ink4a and
p27Kip1. Taken together, targeting of ERK1 and ERK2 is suitable for the treatment of
ovarian cancer cells that do not harbor the constitutive active P13 K mutation and the
loss-of-function mutations of the p16 and/or p53 tumor suppressor proteins.
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Abbreviations: CCLE, cancer cell line encyclopedia; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; ERK, extracellular signal-rgulated kinase; MEK, MAPK/ERK
kinase; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositide 3-kinase; RSK, p90 ribosomal S6 kinase; SA, senescence-associated.
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1 | INTRODUCTION
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most tumors occur in more than one gene, and those genes often
include p53, PIK3, APC, PTEN, B-Raf, Ras, and others. For example,

Ovarian cancer is the leading cause of death from gynecological

when taxol or cisplatin is treated, A549 human lung cancer cells

malignancies in women. Early-stage ovarian cancer is asymptomatic,

harboring mutations both at p53 and K-Ras produce chemoresist-

and approximately 75% of patients are already in an advanced stage of

ance.10 Moreover, HER-positive breast cancer cells and head and neck

the disease when diagnosed.1 Although recent progress in the

squamous cell carcinomas those harbor mutations in PI3 K and Ras or

development of anticancer drugs has led to a remarkable increase in

PTEN and PI3 K are resistant to Trastuzumab (also known as

overall survival from various malignancies, including ovarian cancer,

Herceptin: a humanized monoclonal antibody against HER2)11 and

the 5-year survival rate for patients with advanced stage ovarian

Cetuximab (a monoclonal blocking antibody against the epidermal

2

cancer remains low. Conventional surgery and chemotherapy-based

growth factor receptor EGFR),12 respectively. Therefore, although

treatment modules appear to be ineffective in reducing the mortality

particular mutations in a genome may be clearly associated with

rate of ovarian cancer because of its recurrence frequency and

chemoresistance, difficulties in handling of big data by researchers

resistance to chemotherapy. Gene mutations in K-Ras, p53, and/or

have become a substantial hurdle when attempting to reveal or

phosphatidylinositide 3-kinase (PI3 K) are related to chemoresistance in

suggest possible mechanisms related to how chemoresistance is

ovarian cancers.3 For example, K-Ras mutation is associated with

expressed in cancer cells.

cisplatin resistance in ovarian cancer.4 However, mutaome-based

Magnolin is a lignan compound abundantly found in Magnolia spp.

chemoresistance mechanisms in ovarian cancer have not been clearly

and has been widely used as an oriental medicinal herb to treat various

elucidated.

human diseases and conditions including empyema, nasal congestion,

Chemoresistance may be characterized as intrinsic chemoresist-

sinusitis, and inflammation.13 Recently, our research group reported

ance, which is involved in pharmacokinetics/pharmacodynamics by

that that magnolin is capable of suppressing cell proliferation and

limiting drugs uptake, enhancing efflux, or activating detoxification of

transformation by impairing the G1/S cell-cycle transition and

drugs, or extrinsic chemoresistance, which is associated with genetic or

inhibiting the ERKs/RSK2 signaling pathways by direct targeting of

epigenetic alterations of crucial genes.1 Genetic alterations are

the active pockets of ERK1 and ERK2.13 That study also showed that

reflected in DNA sequences and include mutations, deletions,

magnolin inhibits anchorage-independent cell transformation induced

amplifications, and translocations, and can result in the development

by tumor promoters such as EGF.13 However, the biological effects of

and/or the utilization of non-canonical signaling pathways that are not

magnolin as a cancer therapeutic agent have not been fully described.

observed in normal cells.1 Well-characterized signaling pathways

In this study, we investigated the efficacy of magnolin as an inhibitor of

involved in the controlling of cancer development and chemo-

the ERKs/RSK2 signaling axis in cancer cells, as well as the molecular

resistance are the Ras/Raf/MEKs/ERKs/RSKs and PI3 K/Akt/mTOR

mechanism associated with the magnolin resistance of SKOV3 ovarian

signaling pathways, which are generally known to control cell

cancer cells.

proliferation and transformation, cell survival and death, and cell
locomotion including that associated with cancer cell metastasis.5
These features are closed related to cancer cell malignancy and
chemoresistance, which are obtained via an accumulation of genomic
mutations.6 For example, mutations of K-Ras or Raf in the Ras/Raf/

2 | MATERIALS AND METHO DS
2.1 | Reagents and antibodies

MEKs/ERKs/RSKs signaling pathway are frequently observed in

Chemicals such as Tris, NaCl and sodium dodecyl sulfate (SDS) for

cancer cells harboring chemoresistance against paclitaxel or doxoru-

buffer preparation were purchased from Sigma-Aldrich (St. Louis, MO).

bicin in acute lymphoblastic leukemia, melanoma, colon, gastrointesti-

Magnolin extracted from Shin-Yi, the dried flower buds of Magnolia

nal, and non-small-cell lung cancer,7,8 whereas, mutations of PI3 K in

biondii (Magnolia flos), was generously provided by Dr. S.-R. Oh at the

the PI3 K/Akt/mTOR signaling pathway are observed in breast cancer,

Korea Research Institute of Bioscience and Biotechnology. Cell culture

head and neck squamous cell carcinoma, prostate cancer, colon cancer,

media and other supplements were from Life Science Technologies

and non-small-cell lung cancer and are associated with a lack of cell

(Rockville, MD) or Corning (Manassas, VA). Antibodies against p-

sensitivity to anticancer drugs.9 Regardless, the relationships between

ERK1/2 (T202/Y204), p-Akt (S473), p-Akt (T308), p-p90RSK (T359/

genetic alterations and chemoresistance have not been completely

S363), total-ERK, total-Akt, total-RSK, and total-ATF1 were from Cell

described.

Signaling Biotechnology (Beverly, MA). Antibodies against β-actin and

Recently, bioinformatic data obtained from the mutaome database

p-ATF1 (S63) were purchased from Abcam (Cambridge, MA). Anti-

of the Cancer Cell Line Encyclopedia (CCLE) provided the opportunity

bodies against human p16Ink4a, p27Kip1, and anti-rabbit and anti-mouse

to investigate the relationships between chemoresistance and

secondary antibodies conjugated with horseradish peroxidase were

accumulated mutations in the cancer cells. Based on CCLE mutaome

obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies

data, our research group has sought to elucidate the association of a

against CD44 and CD24 were obtained from BioLegend (San Diego,

particular mutation or signaling pathway with chemoresistance, in

CA). The DC protein assay quantification kit was obtained from Bio-

particular, the Ras/Raf/MEKs/ERKs/RSKs and PI3 K/Akt/mTOR

Rad Laboratories (Hercules, CA). Active Akt1 recombinant protein was

signaling pathways. The data indicate that 20–80% of mutations in

purchased from SignalChem (Richmond, BC, Canada). The Cell Titer 96

90
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Aqueous One Solution Reagent [3-(4,5-dimethylthiazol-2-yl)-5-(3-

incubator. Colony numbers were measured and scored by using an

carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt

ECLIPSE Ti inverted microscope and the NIS-Elements AR (V.4.0)

(MTS)] kit for assay of cell proliferation was from Promega (Madison,

computer software program (NIKON Instruments Korea, Gangnam,

WI).

Seoul, Korea).

2.2 | Cell culture

2.5 | Cell-cycle analysis

Human pancreatic cancer cell lines (AsPC-1, BxPC-3, Capan-1, Capan-

TOV-112D (3 × 105) and SKOV3 (3 × 105) cells were seeded into 60-

2, and MIA PaCa-2), human colon cancer cell lines (SW480, HCT 116,

mm dishes and cultured overnight at 37°C in a 5% CO2 incubator. Cells

HT-29, and COLO 205), human breast cancer cell lines (MCF7, MDA-

were treated with vehicle (DMSO) or 15, 30, or 60 µM of magnolin in

MB-231, SKBR3, and BT-474), and human ovarian cancer cell lines

complete medium for 12 h, then trypsinized, washed with ice-cold 1X

(TOV-112D and SKOV3) were purchased from the American Type

PBS, and fixed with ice-cold 70% ethanol. The cells were treated with

Culture Collection (Manassas, VA). The MCF7 and TOV-112D cells

RNase A (200 µg/mL) and propidium iodide (20 µg/mL) for 15 min at

were cultured in minimum essential medium (MEM) supplemented

4°C. The cell-cycle phase distribution was determined by using flow

with 10% fetal bovine serum (FBS) and antibiotics (100 units each of

cytometry (BD FACS Calibur™ flow cytometry, Franklin Lakes, NJ).

penicillin and streptomycin). Capan-1 cells were cultured in Iscove's
modification of Dulbecco's modified Eagle's medium (IDMEM)
supplemented with 20% FBS and antibiotics (100 units each of

2.6 | Western blotting

penicillin and streptomycin). MIA PaCa-2 and MDA-MD-231 cells

To isolate the proteins for western-blot analysis, cells were disrupted

were cultured in DMEM supplemented with 10% FBS and antibiotics

by freezing and thawing in cell lysis buffer (50 mM Tris pH 8.0, 150 mM

(100 units each of penicillin and streptomycin). SW480, COLO 205,

NaCl, 1% NP-40, Roche protease inhibitor cocktail [2.5 mM sodium

SKBR3, BT-474, and SKOV3 cells were cultured in RPMI1640

pyrophosphate, 1 mM β-glycerophosphate, 1 mM sodium vanadate,

supplemented with 10% FBS and antibiotics (100 units each of

and 1 mM phenyl methyl sulfonyl fluoride]), and the supernatant was

penicillin and streptomycin). All cells were maintained at 37°C in a 5%

recovered by centrifugation at 12 000 r/min for 5 min at 4°C. The

CO2 incubator and split at 90% confluence. Cell culture media were

protein concentration was determined by using the DC protein assay

exchanged with each fresh medium every 2 or 3 days.

kit (Bio-Rad) and an equal amount of protein was resolved by
performing SDS-PAGE. The proteins were transferred onto polyvinylidene fluoride (PVDF) membranes using transfer buffer (20 mM Tris-

2.3 | MTS assay

HCl [pH 8.0] containing 150 mM glycine and 20% [v/v] methanol),
3

3

Cells were seeded (AsPC-1, 1 × 10 cells/well; BxPC-3, 1 × 10 cells/

blocked with 5% nonfat dry milk in blocking buffer (1X TBS containing

well; Capan-1, 1 × 103 cells/well; Capan-2, 1 × 103 cells/well; MIA

0.05% Tween 20: [TBS-T]), and hybridized with antibodies against p-

PaCa-2, 1 × 103 cells/well; SW480, 1 × 103 cells/well; HCT 116,

Akt, total-Akt, p-ERK1/2, total-ERK1/2, p-RSK, total-RSK, p-ATF1,

1 × 103 cells/well;

205,

total-ATF1, or β-actin overnight at 4°C. Blots were washed three times

3

HT-29,

3 × 103 cells/well;
3

COLO

MDA-MB-231,

in 1X TBS-T buffer and rehybridized with appropriate HRP-conjugated

1 × 103 cells/well; BT-474, 1 × 103 cells/well; SKBR3, 1 × 103 cells/

secondary antibodies. Western blots were visualized with an enhanced

well; TOV-112D, 2 × 103 cells/well; SKOV3, 1 × 103 cells/well) into

chemiluminescence detection system (Amersham Biosciences, Piscat-

96-well plates in 100 µL of complete medium and incubated for 24 h;

away, NJ, USA) using a ChemiDoc XRS imager system (Bio-Rad

then, treated with vehicle (DMSO) or 15, 30, or 60 µM of magnolin for

Laboratories).

1 × 10 cells/well;

MCF7,

1 × 10 cells/well;

24, 48, or 72 h. To the cells in each well were added 20 µL of the MTSbased CellTiter 96®Aqueous One Solution. The mixture was incubated
for 1 h at 37°C in a 5% CO2 incubator and then absorbance at 492 nm
was measured by using an xMark™ Microplate Absorbance Spectro-

2.7 | Senescence-associated β-galactosidase (SA-βgal) assay

photometer (Bio-Rad Laboratories). Inhibition of cell proliferation by

TOV-112D (2 × 104) and SKOV3 (1 × 104) cells were seeded into 24-

magnolin was evaluated by comparison with the absorbance of a

well plate and cultured for 12 h. The cells were treated with the

vehicle-treated control group over 72 h at 24 h intervals.

indicated doses of magnolin for 24 h, fixed with 4% formalin (250 µL
per well) by incubation for 5 min at room temperature. Then, the cells

2.4 | Anchorage-independent colony growth assay

were added 500 µL of SA-β-gal staining solution (40 mM citric acid/
sodium phosphate [pH 6.0], 2 mM magnesium chloride, 150 mM NaCl,

Cells (8 × 103/well) suspended in 1 mL of top agar containing 1 × BME

5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 1% X-gal)

supplemented with 10% FBS, 0.33% agar, and indicated doses of

and incubated at 37°C in an incubator for 12 h. The cells were

magnolin were plated onto 3 mL of solidified bottom agar containing

observed, and the SA-β-gal-positive cells from computer-derived

1 × BME supplemented with 10% FBS, 0.5% agar, and indicated doses

random images from four different areas were photographed and

of magnolin and then cultured for 10–14 days at 37°C, in a 5% CO2

counted by using Adobe Photoshop (ver. 12.0).
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2.8 | Semi-quantitative reverse transcriptionpolymerase chain reaction
Total RNA (2 µg) was reverse transcribed with N-MLV Reverse
Transcriptase (iNtRON, Seongnam-si, Gyeonggi-do, Korea) and semiquantitative PCR was performed with following primer pairs: IL-6
forward 5′-TGG CTG AAA AAG ATG GAT GC-3′, reverse 5′-TGC AGG
AAC TGG ATC AGG AC-3′; IL-8 forward 5′-ATG ACT TCC AAG CTG

91

of Shin-Yi fraction one treatment (n = 13). Treatments were administered by orally every day for 12 days and tumor growth was measured
twice a week. Tumor volume was calculated from measurements of
diameters of the individual tumor by using the following formula:
tumor volume (mm3) = (length × width × height × 0.52). Treated mice
were monitored until tumors reached 1 cm3 total volume, at which
time mice were euthanatized and tumors extracted.

GCC GTG GCT-3′, reverse 5′-TCT CAG CCC TCT TCA AAA ACT TCT
C-3′; IL-1b forward 5′-TTT GAG TCT GCC CAG TTC CC-3′, reverse 5′TCA GTT ATA TCC TGG CCG CC-3′; MMP-1 forward 5′-CAT GAC TTT
CCT GGA ATT GG-3′, reverse 5′-CCT GCA GTT GAA CCA GCT AT-3′;
MMP-3 forward 5′-ATG GAC AAA GGA TAC AAC AGG GA-3′, reverse
5′-TGT GAG TGA GTG ATA GAG TGG G-3′; β-actin forward 5′-CGT
CTT CCC CTC CAT CG-3′, reverse 5′-CTC CTT AAT GTC ACG CAC-3′.
PCR products were visualized by agarose gel electrophoresis and
ethidium bromide staining.

2.12 | Immunohistofluorescence assay
To confirm the expression of p16Ink4a and p27Kip1 in xenograft tumor
tissues, the paraffin-invaded tumor tissue slide was deparaffinized by
incubation at 60°C for 2 h, rehydrated and unmasked by boiling with
10 mM sodium citrate buffer (pH 6.0) for 10 min. After cooling, the
slide was blocked with 5% goat serum in 0.5% Triton X-100/PBS at RT
for 1 h and hybridized with the indicated antibodies against p16Ink4a
(200:1) and p27Kip1 (200:1) at 4°C overnight. The slide was three times
washed and hybridized with secondary antibodies conjugating Alexa-

2.9 | NF-κB reporter gene assay
TOV-112D (1.5 × 105) and SKOV3 (7 × 104) cells were seeded into 12well plate and cultured overnight. The cell were co-transfected with

568 at RT for 2 h. Images were captured using laser scanning confocal
microscope (LSM 710) and the intensity was analyzed by Image J
computer software program (Ver. 1.6).

NF-κB luciferase reporter plasmid (0.5 μg) and pRL-SV40 Renilla
luciferase reporter plasmid (20 pg) and cultured for 24 h. The cell
were starved in serum-free medium for 16 h, pretreated with magnolin
with indicated doses for 30 min and then co-treated EGF (10 ng/mL)
and magnolin for 24 h. The cells were disrupted, and the firefly
luciferase activity was measured using a VIXTOR X3 (PerkinElmer Inc,

2.13 | Statistical analysis
Data are presented as the mean ± SEM. The Student's t-test was used
to perform statistical analysis of single comparisons. A probability
value of P < 0.05 was used as the criterion for statistical significance.

Waltham, MA). The firefly luciferase activity was normalized by Renilla
luciferase activity to equalize the transfection efficiency.

2.10 | Cancer stem cell analysis
Cells (TOV-112D, 6 × 103/20 µL; SKOV3, 6 × 103/20 µL) were seeded
as 20 µL drops onto the lids of 100-mm culture dishes by using hanging
drop method14 and then cultured for 48 h at 37°C in a 5% CO2
incubator. Cells were dissociated by using accutase (Sigma-Aldrich),
harvested, and hybridized with CD44 (4 ng/µL) or CD24 (2 ng/µL) in
the dark for 2 h at 4°C. The cells were counted by flow cytometry (BD
FACS Calibur™ flow cytometer).

3 | RESULTS
3.1 | Magnolin suppresses cell proliferation of TOV112D cells among tested pancreatic, colon, breast,
and ovarian cancer cells
Recently, our research group demonstrated that magnolin, a natural
compound abundantly found in Shin-Yi, inhibits cell proliferation and
transformation induced by tumor promoters such as EGF in JB6 Cl41
cells.13 Molecular targeting against kinases demonstrated that
magnolin targets the active pockets of ERK1 and ERK2, which are
important kinases transducing the activation signaling of EGFR/Ras/
Raf/MEKs to RSK and/or transcription factors that are highly activated

2.11 | Xenograft athymic animal experiment

in many solid human cancers,15 at approximately 87 and 16 nM of IC50,
respectively.13 However, the anticancer activity of magnolin has not

Athymic nude mice (6 weeks old) were obtained from Charles River

been clearly elucidated. To explore the anticancer activity of magnolin,

(Seoul, South Korea) and maintained under specific pathogen-free

we utilized several cancer cells including pancreatic cancer cells (AsPC-

conditions with a light/dark cycle of 12/12 h in accordance with the

1, BxPC-3, Capan-1, Capan-2, and MIA PaCa-2), colon cancer cells

guideline approved by the Institutional Animal Care and Use

(SW480, HCT 116, HT-29, and COLO 205), breast cancer cells (MCF7,

Committee (approval number: 2014-013-02) at The Catholic Univer-

MDA-MB-231, SKBR3, and BT-474), and ovarian cancer cells (TOV-

sity of Korea. After 1 week of acclimation, the mice were implanted

112D and SKOV3). Since it has been reported that cancer cells

subcutaneously with TOV-112D (6 × 106 cells) in the right dorsal flank

originating from different organs or tissues harbor predominately

and monitored until tumor volume had grown to 100 mm3. Mice

different mutation(s) in different genes,15,16 we firstly analyzed

3

harboring a tumor larger than 100 mm were randomly divided into

mutations of oncogenes and tumor suppressor genes against

two groups for vehicle treatment (control group: n = 12) or 100 mg/kg

the aforementioned cancer cell lines by searching the CCLE

92
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(https://portals.broadinstitute.org/ccle_legacy/home) mutaome data-

not have significant inhibitory effect on proliferation in these cell lines

base (Table 1). The results showed that pancreatic cancer cells

(Figure 1B and C). An interesting result was obtained from the ovarian

exhibited gain-of-function mutations, mainly in MAPK, and loss-of-

cancer cells TOV-112D (harboring gain-of-function mutation in β-

function mutations, mainly in p16, p53, and SMAD4 (Table 1). The

catenin) and SKOV3 (harboring gain-of-function mutation in PI3 K and

colon cancer (COLO 205, HT-29, SW480, and HCT 116) and breast

loss-of-function mutation in p15 and p53 tumor suppressors) with only

cancer (MCF7, BT-474, MDA-MB-231, and SKBR3) cell lines showed

TOV-112D ovarian cancer cells showing an inhibitory effect of

variable gain-of-function mutations in both PI3 K and MAPK or Wnt

magnolin on cell proliferation, and that effect was dose-dependent

and MAPK signaling pathways, respectively (Table 1). Interestingly, the

(Figure 1D). These results indicate that investigations of chemothera-

majority of these cell lines harbored gain-of-function mutations in

peutic applications that target ERK1 and ERK2 can benefit to treat

double or triple signaling pathways and single tumor suppressor

cancer cells with non-mutated tumor suppressor linkage.

signaling pathways such as p16 or p53 (Table 1). Furthermore, TOV112D ovarian cancer cells had a mutation in β-catenin but not in Ras or
PI3 K. In contrast, SKOV3 ovarian cancer cells had a constitutively
active mutation of PI3 K together with loss-of-function mutations of

3.2 | Magnolin inhibits cell-cycle transition and
colony growth in TOV-112D, but not in SKOV3

the p16 and p53 tumor suppressors (Table 1). In addition, we analyzed

The Ras/Raf/MEKs/ERKs/RSK2 signaling pathway has an important

the magnolin effects on cell proliferation in pancreatic, colon, breast,

role in cell proliferation and cancer development by stimulation of

and ovarian cancer cell lines. Since pancreatic cancer cells harbored

growth factors.17 Our previous results demonstrated that inhibition of

mainly gain-of-function mutation in K-Ras and MAP2K4 and loss-of-

ERK1 and ERK2 by magnolin suppresses G1/S cell-cycle transition in

function mutation in p16 and p53 (Table 1), we expected that inhibition

premalignant JB6 Cl41 cells.13 Therefore, based on the results

of ERK1 and ERK2 might sensitize pancreatic cancer cell proliferation

presented in Figure 1 and Table 1, we hypothesized that magnolin

to directly inhibit cell proliferation. Unexpectedly, pancreatic cancer

might differentially inhibit cell-cycle arrest in TOV-112D and SKOV3

cell proliferation was not affected by magnolin treatment (Figure 1A).

ovarian cancer cells. To examine that hypothesis, we initially

Moreover, the SW480 and HCT116 colon cancer cells and the MCF-7,

conducted cell-cycle analysis under normal cell culture conditions.

MDA-MB-231, and SKBR3 breast cancer cells showed about 20–30%

We observed that magnolin treatment increased the populations of G1

cell proliferation inhibition at the 60 µM magnolin treatment

and G2/M phase cells in TOV-112D ovarian cancer cells in a dose-

concentration along with dose-dependency; regardless, magnolin did

dependent manner (Figure 2A, left graph). In contrast, the population

TABLE 1

CCLE mutaome analysis of genes involved in chemoresistance

O, gain-of-function; X, loss-of-function; Δ, not determined.
Summary of Cancer Cell Line Encyclopedia (CCLE) mutation data for gain/loss-of-function mutations in human cancer cell lines.
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FIGURE 1 Screening of cancer cell lines showing results for sensitivity against magnolin. (A) Pancreatic cancer cells (AsPC-1, 1 × 103 cells/
well; BxPC-3, 1 × 103 cells/well; Capan-1, 1 × 103 cells/well; Capan-2, 1 × 103 cells/well; MIA PaCa-2, 1 × 103 cells/well), (B) colon cancer cells
(SW480, 1 × 103 cells/well; HCT 116, 1 × 103 cells/well; HT-29, 3 × 103 cells/well; COLO 205, 1 × 103 cells/well), (C) breast cancer cells
(MCF7, 1 × 103 cells/well; MDA-MB-231, 1 × 103 cells/well; BT-474, 1 × 103 cells/well; SKBR3, 1 × 103 cells/well), and (D) ovarian cancer cells
(TOV-112D, 2 × 103 cells/well; SKOV3, 1 × 103 cells/well) were seeded into 96-well cell culture plates and cell proliferation was measured at
24 h intervals over 96 h by performing MTS assays. The graphs denote inhibition percentage of cell proliferation at 72 h compared to nonmagnolin-treated control cells. (A–D) Data were obtained from three independent experiments, values are presented are means ± SEM.
Biological significance was determined by comparison with the non-magnolin-treated control group and statistical significance values
(*P < 0.01) were calculated by Student's t-test

of S phase cells decreased under magnolin treatment in a dose-

50% at 30 µM in soft agar (Figure 2B, upper panels and graph), and the

dependent manner (Figure 2A, left graph). However, no significant

inhibitory effect of magnolin on colony growth in soft agar increased in

changes of cell cycle phases were observed in SKOV3 cells at 60 µM of

a dose-dependent manner (Figure 2B, upper panels and graph). In

magnolin (Figure 2A, right graph). These results further suggested that

contrast, SKOV3 cells did not alter the colony growth by magnolin

magnolin may inhibit TOV-112D colony growth, but not that of

treatment in soft agar (Figure 2B, bottom panels and graph). Taken

SKOV3, under anchorage-independent conditions. To confirm that

together with Table 1 and Figures 1 and 2, these results demonstrate

hypothesis, we conducted soft agar assays. We observed that

that magnolin treatment may be useful for inhibiting the growth of

magnolin inhibited colony growth of TOV-112D cells by approximately

cancer cells harboring gain-of-function mutation in the Wnt signaling

94
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FIGURE 2 Magnolin sensitivities of TOV-112D and SKOV3 ovarian cancer cells on cell proliferation and colony growth. (A) Magnolin
inhibited cell proliferation of TOV-112D cells, but not SKOV3 cells. TOV-112D (8 × 105 cells) and SKOV3 (4 × 105 cells) cells were seeded
into 60-mm dishes and cultured overnight. The cells were treated with indicated doses of magnolin for 12 h, and then cell-cycle cell phase
distribution was analyzed by using flow cytometer as described in Materials and Methods. (B) Magnolin suppressed anchorage-independent
colony growth of TOV-112D cells, but not SKOV3 cells. TOV-112D or SKOV3 cells (8 × 103 cells) suspended in BME medium containing 0.3%
agar supplemented with 10% FBS and vehicle (DMSO) or 15, 30, or 60 µM of magnolin. Cultures were maintained at 37°C in a 5% CO2
incubator for 20 days, and the colonies were counted under an ECLIPSE Ti inverted microscope using the NIS-Elements AR (V. 4.0) computer
software program. (A and B) Data were obtained from three independent experiments, values presented are means ± SEM. Biological
significance was determined by comparison with the non-magnolin-treated control group and statistical significance values (*P < 0.05,
**P < 0.01) were obtained by Student's t-test
pathway, such as the β-catenin mutation in ovarian cancer. The results

of MAPK, Akt as a member of PI3 K, and ATF1 as a member of RSK2

also suggest that ovarian cancer cells harboring a constitutively active

downstream targets in cancer cell lines such as Capan-1, MIA PaCa-2,

mutation of PI3 K and loss-of-function mutations of p16 and p53

MDA-MB-231, MCF7, HCT116, HT-29, TOV-112D, and SKOV3

tumor suppressor proteins can show chemoresistance to ERK1 and

(Figure 3A). We observed that the phosphorylation levels of ERK1/2

ERK2 inhibitors.

were higher in ovarian cancer cells than in other cancer cells (Figure 3A,
lane 7 and 8). Interestingly, the phospho-RSK level at Thr359/363, an

3.3 | Magnolin sensitivity associated with ERK1/2
phosphorylation levels in ovarian cancer cells

amino acid directly phosphorylated by ERK1/2, was higher in MDAMB-231, HCT116, and HT-29 cells, whereas these cells contained
relatively low levels of phospho-ERK1/2 (Figure 3A, lane 3, 5, and 6)

To examine the signaling pathways related to the sensitivities of

compared to the ovarian cancer cells (Figure 3A, lane 7 and 8).

magnolin on cell proliferation and colony growth in soft agar, we

Moreover, the phosphorylations of Akt at Thr308, an amino acid

analyzed the phospho-protein profiles of ERKs and RSKs as members

directly phosphorylated by PI3 K and PDK1, and Ser473, a target
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FIGURE 3 Comparison of the phospho-protein profiles in two ovarian cancer cell lines. (A) Phospho-protein profiles in cancer cells.
Indicated cancer cells (1 × 106 cells) were seeded into 100-mm cell culture dishes and cultured until cell confluence of approximately 90%.
The proteins extracted from indicated cells were visualized by western blotting using specific antibodies as indicated. (B) Activation protein
profiles following EGF stimulation of ovarian cancer cells. TOV-112D (2 × 106 cells) and SKOV3 (1 × 106 cells) cells were seeded into 100-mm
cell culture dishes, cultured for 24 h, and starved with non-FBS containing medium for 18 h. Cells were stimulated with EGF (10 ng/mL) for
the indicated time course. The proteins were extracted and visualized by western blotting using specific antibodies as indicated. (C) Inhibitory
phospho-protein profiles by co-treatment of EGF and magnolin in ovarian cancer cells. TOV-112D (2 × 106 cells) and SKOV3 cells (1 × 106
cells) were seeded into 100-mm cell culture dishes, cultured for 24 h, and starved with non-FBS containing media for 18 h. The cells were
pretreated with the indicated dose of magnolin for 30 min and then co-treated with EGF (10 ng/mL) for 30 min. The proteins were extracted
and visualized by western blotting using specific antibodies as indicated. (D) Comparison of phospho-ATF1 protein levels in ovarian cancer
cells. TOV-112D (2 × 106 cells) and SKOV3 (1 × 106 cells) cells were seeded into 100-mm cell culture dishes, cultured for 24 h, and starved
with non-FBS containing medium for 18 h. The cells were stimulated with EGF (10 ng/mL) for the indicated time course. The proteins were
extracted and phospho-ATF1 and total-ATF1 were visualized by western blotting using specific antibodies as indicated. (E) Magnolin inhibited
the phosphorylation of ATF1 in TOV-112D cells, but not in SKOV3 cells. TOV-112D (2 × 106 cells) and SKOV3 (1 × 106 cells) cells were
seeded into 100-mm cell culture dishes, cultured for 24 h, and treated with 30 µM of magnolin for the indicated time course. The proteins
were extracted and phospho-ATF1 and total-ATF1 were visualized by western blotting using specific antibodies as indicated. (A–E) β-actin
was used for the internal control to verify equal protein loading
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amino acid phosphorylated by mTOR complex 2 (mTORC2), were

stimulation (Figure 3B). However, phospho-RSK at Thr359/Ser363,

strongly observed in SKOV3 cells compared to the other cancer cells

phospho-RSK2 at S227, and total protein levels of RSKs were higher in

(Figure 3A, lane 8 vs. lane 1–7). Since ovarian cancer cells showed a

SKOV3 cells than in TOV-112D cells (Figure 3B). To examine the

marked difference in phospho-ERK1/2 and phospho-Akt levels, we

effects of magnolin on the phosphorylation levels in signaling

further examined the EGF-stimulated responsiveness of phospho-

pathways, we co-stimulated TOV-112D and SKOV3 cells with EGF

protein profiles under complete medium-supplemented normal cell

and magnolin. We found that magnolin suppressed the EGF-induced

culture conditions (Figure 3B). The results indicated that phospho-

RSK phosphorylation at Thr359/Ser363 in a dose-dependent manner

ERK1/2 and phospho-RSK levels were induced by EGF stimulation in

as similar as a decrease of ERK1/2 phosphorylation (Figure 3C).

TOV-112D cells (Figure 3B). Interestingly, SKOV3 cells showed only a

Interestingly, although phosphorylation of ERK1/2 was very weakly

marginal increase in ERK1/2 phosphorylation following EGF

increased by EGF stimulation in SKOV3 cells, the phosphorylation
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levels of RSKs at Thr359/Ser363 were also markedly increased by EGF

that magnolin treatment increased SA-β-gal-positive cell population in

stimulation in SKOV3 cells (Figure 3C). Additionally, magnolin

TOV-112D cells in a dose-dependent manner (Figure 4A). In contrast,

minimally reduced the EGF-induced phospho-RSK levels in SKOV3

we did not observed SA-β-gal-positive SKOV3 cells while the magnolin

cells compared to that in TOV-112D cells (Figure 3C). Although the

concentration was increased to 60 µM (Figure 4A). The SA-β-gal-

increased ratio for phosphorylation of ATF1 at Ser63, which is a target

positive staining of TOV-112D cells was not limited by magnolin, but

amino acid phosphorylated by RSK2,

18

was similarly increased in both

observed in other ERK inhibitors such as SCH772984 and LY321449

TOV-112D and SKOV3 cells, the SKOV3 cells showed a more marked

and a MEK inhibitor U0126 (Figure 4B). As expected, TOV-112D cells

increase in phopsho-ATF1 levels because of high degree of elevated

was showed the SA-β-gal-positive cells by specific inhibition of ERKs

ATF1 protein levels in SKOV3 cells (Figure 3D). Moreover, we

using SCH772984, but not in SKOV3 (Supplementary Figure S1). To

confirmed that magnolin suppressed ATF1 phosphorylation only in

examine whether magnolin-induced senescence is the cellular

TOV-112D cells, not in SKOV3 cells, under normal cell culture

senescence or senescence-associated secretory phenotype (SASP),

conditions (Figure 3E). Taken together with the results in our previous

we firstly examine the transactivation activity of NF-κB, which is an

study,13 these results demonstrate that molecular targeting of ERK1

important transcription factor inducing gene expression of SASP

and ERK2 with magnolin can suppress ovarian cancer cell lines

related genes.21 Our results demonstrated that magnolin suppressed

harboring a general MAPK signaling cascade such as TOV-112D.

NF-κB transactivation activity (Figure 4C) as similar as our previous

These results also suggest that cells containing a bypass signaling

report.22 In contrast, the inhibition of NF-κB transactivation activity

pathway of ERK1/2 may induce chemoresistance against therapeutic

was not observed in SKOV3 cells (Figure 4C). Moreover, magnolin did

compounds that target RSK upstream signaling molecules in Ras/Raf/

not induce or not alter the expression of IL-6, IL-8, IL-1β, MMP-1, and

MEKs/ERKs signaling axis.

MMP-3 (Figure 4D), which are well known the representative SASP
markers.23 Notably, NF-κB transactivation activity induced by EGF

3.4 | Magnolin induces cellular senescence in TOV112D, but not in SKOV3

stimulation was suppressed by magnolin treatment (Figure 4E).
Importantly, suppressed ERK phosphorylation by transfection of
dominant negative of ERK1/2 (Figure 4F) induced SA-β-gal-positive

The suppression of cancer cell proliferation induces cellular senes-

cell population (Figure 4G). Taken together, inhibition of ERK1/2 by

cence.19 Our results demonstrated that magnolin treatment in TOV-

magnolin induces cellular senescence, not SASP, in TOV-112D,

112D ovarian cancer cells inhibits cell proliferation by enhancing

resulted in inhibition of TOV-112D proliferation.

accumulation of cells at the G1 cell-cycle phase (Figures 1D and 2A).
Moreover, Ras activation induces the Raf/MEKs/ERKs/RSK2 signaling
axis, resulting in increase of cancer cell proliferation.20 Taken together,
these observations suggest that inhibition of cell proliferation by

3.5 | Magnolin suppresses cancer growth of TOV112D in vivo

magnolin might induce cellular senescence in TOV-112D cells. To

A recent study demonstrated that cancer cells harboring cancer stem

examine that hypothesis, we conducted senescence associated (SA)-β-

cell properties resist cellular senescence.24 To examine whether

gal assays using TOV-112D and SKOV3 cells (Figure 4A). We observed

SKOV3 cells harbor cancer stem cell properties, we undertook sphere

3

FIGURE 4 Magnolin suppresses TOV-112D ovarian cancer growth, but not SKOV3 growth, in xenograft athymic nude mice by inducing
cellular senescence. (A) Magnolin induced SA-β-gal staining in TOV-112D cells, but not in SKOV3 cells. TOV-112D (2 × 104) and SKOV3
(1 × 104) cells were seeded into 24-well plates, cultured, and treated with indicated doses of magnolin for 24 h. (B) ERK inhibition induces SAβ-gal staining. TOV-112D (2 × 104) cells were seeded into 24-well plates, cultured, and treated with indicated doses of magnolin, SCH772984,
LY3214996 and U0126 for 24 h. (C) Magnolin suppresses NF-κB transactivation activity. NF-κB-luciferase reporter plasmids were transiently
transfected into TOV-112D and SKOV3 cells and cultured for overnight. The cells were treated with indicated doses of magnolin for 12 h and
firefly luciferase activities were measured. The equal transfection of NF-κB-luc was compensated using pRL-SV40 Renilla luciferase control
plasmids. (D) Magnolin did not alter the gene expression of SASP makers. Total RNA extracted from the magnolin treated TOV-112D and
SKOV3 were utilized to measure the gene expression of SASP maker genes by PCR as indicated. The PCR products were visualized by
ethidium bromide containing agarose-gel electrophoresis under UV lamp. β-actin was used for the internal control to verify equal
experimental condition. (E) Magnolin inhibits EGF-induced NF-κB transactivation activity. NF-κB luciferase reporter plasmids were transfected
into TOV-112D cells, starved and treated with EGF or EGF/magnolin for 12 h and firefly luciferase activity was measured. The equal
transfection of NF-κB-luc was compensated using pRL-SV40 Renilla luciferase control plasmids. (F) Dominant negative (DN)-ERK suppresses
ERK phosphorylation. The expression vector encoding DN-ERK was transfected into TOV-112D and confirmed the suppression of ERK
phosphorylation by Western blotting. β-actin was used for the internal control to verify equal protein loading. (G) DN-ERK induces SA-b-gal
staining. The pDN-ERK expression vector was transfected into TOV-112D cells and cultured 24 h. The cells were stained with X-gal and
observed under a light microscope (X400). (A, B, and G) The cells were fixed, and cellular senescence was observed under a light microscope
after SA-β-gal staining. The SA-β-gal-positive cells from computer-derived random images from four different areas were measured and the
relative abundance (%) of SA-β-gal-positive cells are presented in lower graph. (A–C, E, and G) Data were obtained from three independent
experiments, values presented are means ± SEM. Biological significance was determined by comparison with the non-magnolin-treated or
indicated control group and statistical significance values (*P < 0.05, **P < 0.01) were determined by Student's t-test
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colony formation of TOV-112D and SKOV3 cells. Using sphere-

4A and B, we hypothesized that magnolin might suppress TOV-112D

formed colonies, we examined the cell populations expressing cancer

cancer cell growth in athymic nude mice. Unfortunately, there was

stem cell markers via flow cytometry using CD24 and C44 antibodies.

difficulty obtaining a sufficient quantity of magnolin with a purity level

The results demonstrated that SKOV3 cells produced increased

of at least 97% or higher. Thus, we utilized a half purified Shin-Yi

CD44+/CD24− cell populations, which is a typical cancer stem cell

fraction 1 in which magnolin was approximately 53% of the total

In contrast, the CD44 /

fraction. We implanted TOV-112D cells (6 × 106 cells) in the right

CD24 cell population in TOV-112D cells did not significantly change

dorsal flank of athymic nude mice, and when tumor growth reached

after sphere formation (Figure 5A). Taken together with Figures 2B and

approximately 100 mm3, we randomly divided the mice into two

marker of ovarian cancer stem cells.

25,26

+

−

FIGURE 5 Magnolin induces cellular senescence in vivo. (A) SKOV3 cells harbor ovarian cancer stem cell properties. TOV-112D (6 × 103/
20 µL) and SKOV3 (6 × 103/20 µL) cells were applied to form mono spheres (100 spheres) by using hanging drop culture for 48 h. The cells
were detached with accutase and hybridized with CD24-APC- or CD44-FITC-conjugated antibodies for 2 h on ice, and the CD24- and CD44positive/negative populations were analyzed by flow cytometry. (B-D) Magnolin suppressed TOV-112D cancer growth in the xenograft
animal model. Athymic nude mice maintained under specific pathogen-free conditions and a light/dark cycle of 12/12 h underwent
subcutaneous implantation of TOV-112D cells (6 × 106 cells) in the right dorsal flank in accordance with the approved animal care guideline as
described in Materials and Methods. When tumors had grown to over 100 mm3, mice were divided into two groups and orally administrated
vehicle (control group: n = 12) or Shin-Yi fraction 1 magnolin extract (100 mg/kg, n = 13) for 12 days every day. Body weight (B) and tumor
growth (C, *P < 0.05) were measured twice a week. At the end of the treatment period, the mice were euthanatized and tumors were excised
(D). (E) The tumor tissues obtained from vehicle and fraction I administered experimental group were prepared tissue slides for histological
analysis. The tissue slides were processes for immunohistofluorescence analysis as described in “Materials and Methods.” The protein levels
of p16Ink4a and p27Kip1 were visualized by hybridization using specific primary and Alexa-568. Fluorescence images were detected and
captured under confocal microscope. DAPI was used for nuclei staining
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groups and orally administered vehicle or 100 mg/kg of Shin-Yi

(Figure 3B), which are critically important for RSK activation.20 The

fraction 1 every day for 12 days. The administration of fraction I did not

results showing that SKOV3 cells exhibited magnolin resistance during

affect mouse body weight change during the treatment period

cell proliferation and colony growth in soft agar (Figure 1D and 2B)

(Figure 5B), indicating that Shin-Yi fraction 1 had no apparent toxicity.

suggest that there may be another contact point, one that does not

However, the results showed that Shin-Yi fraction 1 significantly

involve ERK1 or ERK2.

suppressed growth of TOV-112D tumors in athymic nude mice

Cancer cells harbor the ability to sustain chronic proliferation. In

(Figure 5C and D). Since magnolin induced cellular senescence

contrast, normal tissues exhibit controlled production and release of

(Figure 4), we further analyzed protein levels of p16Ink4a and

growth-promoting signals, ensuring homeostasis of cell numbers for

p27Kip1, which were typical cellular senescence markers, in xenograft

the maintenance of normal tissue function.35 Thus, elucidation of the

tumor tissues. We found that tumor tissues from fraction I

mechanisms regulating cell proliferation in normal cells and tissues is

administered mice showed higher p16Ink4a and p27Kip1 protein levels

important because cancer cells acquire the capability to sustain

than that of vehicle administered mice (Figure 5E). Taken together,

proliferation via various alternative signaling pathways.36 Cancer cells

these results demonstrate that magnolin may have application as a

may produce auto-growth factor themselves, resulting in autocrine

cancer therapeutic agent against ovarian cancer cells that do not have

proliferative stimulation.37 Moreover, loss of regulatory mechanisms

a gain-of-function mutation in PI3 K and a loss-of-function mutation in

controlling cell proliferation can also result from mutation.38 For

p16 and p53 tumor suppressor proteins.

example, human melanomas contain about 40% of the activating
mutations in B-Raf, resulting in constitutive activation signaling
through the Raf to MAPK pathways.39 Similarly, mutation in the

4 | DISCUSSION

catalytic subunit of PI3 K has been reported in several different human
cancers,40 and the signaling pathway through PI3 K to Akt/mTOR

Chemoresistance of cancer cells is principally obtained via two

kinase has been reported to coordinate and sustain cancer cell

different pathways, intrinsic and extrinsic, and such resistance can

proliferation, growth, and division via regulation of cellular metabolism

affect cancer cell survival and stress tolerance.27 The intrinsic pathway

and homeostasis.41 Recently, oncogenes such as K-Ras have been

has an important role in drug metabolism in the liver by activating

shown to mediate cellular and metabolic transformation during

phase I, phase II, and phase III drug metabolizing enzymes.28 The

tumorigenesis,42 indicating that MAPK and PI3 K signaling pathways

extrinsic pathway is involved in genetic and epigenetic chemo-

are related to the maintenance of homeostasis in normal and cancer

resistance alterations, resulting in alteration of gene expressions.27

cells.43 One path to the induction of cancer chemoresistance is the

Generally, genetic alteration of tumor suppressor proteins such as p16,

bypassing of cellular senescence, a self-protection mechanism,44

p21, and p53 has a key role in the chemoresistance of various cancer

resulting in immortalization and malignancy. An accumulation of data

cells.

29

However, signaling studies focused on a specific signaling

has indicated that the loss-of-function of tumor suppressors, such as

pathway have not fully elucidated the complicated signaling networks

retinoblastoma (RB), p53, and p16, has a critically important role in the

involved in responses to diverse intrinsic and extrinsic stimuli.30 To

process of bypassing cellular senescence.45,46 Moreover, the loss of

assist in that elucidation, the National Cancer and National Human

p53 and the tumor suppressor PTEN bypasses cellular senescence to

Genome Research Institutes have provided mutaome data obtained

form prostate cancer in mice.46 Interestingly, mutations in the Ras-

from various cancer cells.

31

Those data can provide important clues in

mediated MAPK family, especially the B-Raf valine-to-glutamate

researching the relationship between genetic alteration and

mutation, encourage enhancement of tumorigenesis in melanoma by

chemoresistance.

evasion of p53-dependent senescence.47 Our current study demon-

One of the widely reported ways to obtain cancer chemo-

strated that TOV-112D harbors wildtype p16 and p53 and SKOV3

resistance is to alter the molecular targets of therapeutic agents by

contains mutant p16 and p53 (Table 1). Interestingly, magnolin

modulating gene expression levels or bypassing the target signaling

sensitivity on the cell proliferation was obverted in TOV-112D without

pathway.32,33 Although MAPK and PI3 K/Akt signaling pathways are

alteration of SASP markers (Figure 4D), indicated that magnolin-

involved in cancer development and chemoresistance, they are

mediated senescence is cellular senescence that is associated with cell

generally recognized as two independent but parallel pathways.33

cycle arrest (Figure 2A). In contrast, we further observed that magnolin

However, recent interactome studies have indicated that these two

induced the protein levels of p16Ink4a and p27Kip1, critical markers for

signaling pathways influence each other in different signaling

cellular senescence, in xenograft tissues (Figure 5E). Unfortunately, we

transduction processes, both negatively and positively, via multiple

could detect the SA-β-gal activity in tumor tissues because the tissues

cross-talking points.34 In this study, we observed that ERK1/2

were fixed in 4% formalin for long period. These results suggest that

phosphorylation resulting from EGF stimulation in SKOV3 cells was

constitutive active mutation in MAPK and PI3 K signaling pathways

notably weak compared to that in TOV-112D cells (Figure 3B).

have a key role in bypassing cellular senescence.

Interestingly, SKOV3 cells contained high levels of Akt phosphoryla-

Recently, genomic analysis of ovarian carcinoma indicated that

tion at Thr308 and Ser473, which are critically important to full

TP53 mutations are observed about 96% of high-grade serious ovarian

activation of Akt. Importantly, SKOV3 cells showed very strong

cancers.48 They also found additional somatic mutations in genes,

responsiveness for RSK phosphorylation at Thr359 and Thr363

including NF1, BRACA1, BRCA2, RB1, and CDK12, with low
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prevalence but statistically recurrence.48 The somatic mutations of
BRCA1 and 2 are associated with other genes that are involved in DNA
repair in high-grade ovarian cancers.48 However, high-grade ovarian
cancer are associated with about 10–20% germline mutations in
BRCA1 and 2,49 indicated that tumor suppressors plays a key role in
ovarian cancer development. Moreover, it is clear that constitutive
active mutations in MAPK signaling pathway was observed about each
11% of total epithelial ovarian cancers in B-Raf and K-Ras genes,
respectively.50 On the other hand, constitutive active mutation of
PI3 K (PI3KCA) and loss-of-function of PTEN was observed with about
6.7 and 20% of the total epithelial ovarian cancers.50,51 Analysis of the
CCLE mutaome data has indicated that SKOV3 cells contain a
constitutively active mutation in PI3 K and loss-of-function mutations
in p16 and p53 (Table 1). Moreover, SKOV3 cell showed negative
results following SA-β-gal staining and magnolin treatment, whereas,
the opposite results were obtained with TOV-112D cells (Figure 4A).
Importantly, we observed that the ovarian cancer cell marker CD44+/
CD24− was enriched in sphere-formed SKOV3 cells, but not in sphereformed TOV-112D cells (Figure 5A), thereby indicating that ERK1 and
ERK2 targeting is suitable for the treatment of ovarian cancer cells that
do not contain a constitutively active mutation in PI3 K and loss-offunction mutations in the p16 and p53 tumor suppressor proteins.

ACKNOWLEDGMENTS
This study was supported by the Research Fund of The Catholic University
of Korea (M-2018-B0002-00011), the Ministry of Science, ICT and
Future Planning (NRF-2017R1A2B2002012, −2017M3A9F5028608
and −2017R1A4A1015036), and the Ministry of Education (BK21PLUS
grant NRF-22A20130012250).

CONFLICT OF INTEREST
The authors declare no competing financial interest.

ORCID
Yong-Yeon Cho

http://orcid.org/0000-0003-1107-2651

REFERENCES
1. Liu M, Chan D, Ngan H. Mechanisms of chemoresistance in human
ovarian cancer at a glance. Gynecol Obstet. 2012;2:e104.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin.
2015;65:5–29.
3. Brachova P, Thiel KW, Leslie KK. The consequence of oncomorphic
TP53 mutations in ovarian cancer. Int J Mol Sci. 2013;14:
19257–19275.
4. Holford J, Rogers P, Kelland LR. Ras mutation and platinum resistance
in human ovarian carcinomas in vitro. Int J Cancer. 1998;77:94–100.
5. Steelman LS, Chappell WH, Abrams SL, et al. Roles of the Raf/MEK/
ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and
sensitivity to therapy-implications for cancer and aging. Aging (Albany
NY). 2011;3:192–222.

ET AL.

6. McCubrey JA, Steelman LS, Chappell WH, et al. Ras/Raf/MEK/ERK
and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can
result in therapy resistance and how to overcome resistance.
Oncotarget. 2012;3:1068–1111.
7. Jin W, Wu L, Liang K, Liu B, Lu Y, Fan Z. Roles of the PI-3K and MEK
pathways in Ras-mediated chemoresistance in breast cancer cells. Br J
Cancer. 2003;89:185–191.
8. Macerelli M, Caramella C, Faivre L, et al. Does KRAS mutational status
predict chemoresistance in advanced non-small cell lung cancer
(NSCLC)? Lung Cancer. 2014;83:383–388.
9. Arcaro A, Guerreiro AS. The phosphoinositide 3-kinase pathway in
human cancer: genetic alterations and therapeutic implications. Curr
Genomics. 2007;8:271–306.
10. Yang L, Zhou Y, Li Y, et al. Mutations of p53 and KRAS activate NFkappaB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Cancer Lett. 2015;357:520–526.
11. McCubrey JA, Steelman LS, Kempf CR, et al. Therapeutic resistance
resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/
mTOR signaling pathways. J Cell Physiol. 2011;226:2762–2781.
12. Wang Z, Martin D, Molinolo AA, et al. MTOR co-targeting in
cetuximab resistance in head and neck cancers harboring PIK3CA
and RAS mutations. J Natl Cancer Inst. 2014;106.
13. Lee CJ, Lee HS, Ryu HW, et al. Targeting of magnolin on ERKs inhibits
Ras/ERKs/RSK2-signaling-mediated neoplastic cell transformation.
Carcinogenesis. 2014;35:432–441.
14. Seiler AE, Spielmann H. The validated embryonic stem cell test to
predict embryotoxicity in vitro. Nat Protoc. 2011;6:961–978.
15. Cho YY. RSK2 and its binding partners in cell proliferation,
transformation and cancer development. Arch Pharm Res. 2017;40:
291–303.
16. Cho YY. Molecular targeting of ERKs/RSK2 signaling in cancers. Curr
Pharm Des. 2017;23:4247–4258.
17. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated
protein kinase cascade for the treatment of cancer. Oncogene.
2007;26:3291–3310.
18. Liu K, Cho YY, Yao K, et al. Eriodictyol inhibits RSK2-ATF1 signaling
and suppresses EGF-induced neoplastic cell transformation. J Biol
Chem. 2011;286:2057–2066.
19. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol.
2011;192:547–556.
20. Cho YY, Yao K, Kim HG, et al. Ribosomal S6 kinase 2 is a key regulator
in tumor promoter induced cell transformation. Cancer Res.
2007;67:8104–8112.
21. Chien Y, Scuoppo C, Wang X, et al. Control of the senescenceassociated secretory phenotype by NF-kappaB promotes senescence
and enhances chemosensitivity. Genes Dev. 2011;25:2125–2136.
22. Lee CJ, Lee MH, Yoo SM, et al. Magnolin inhibits cell migration and
invasion by targeting the ERKs/RSK2 signaling pathway. BMC Cancer.
2015;15:576.
23. Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescenceassociated secretory phenotype: the dark side of tumor suppression.
Annu Rev Pathol. 2010;5:99–118.
24. Vinogradov S, Wei X. Cancer stem cells and drug resistance: the
potential of nanomedicine. Nanomedicine (Lond). 2012;7:597–615.
25. Jaggupilli A, Elkord E. Significance of CD44 and CD24 as cancer stem cell
markers: an enduring ambiguity. Clin Dev Immunol. 2012;2012:708036.
26. Meng E, Long B, Sullivan P, et al. CD44+/CD24- ovarian cancer cells
demonstrate cancer stem cell properties and correlate to survival. Clin
Exp Metastasis. 2012;29:939–948.
27. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways:
cross-talk and compensation. Trends Biochem Sci. 2011;36:320–328.
28. Sim S, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of
drug-metabolizing enzymes: a recent update on clinical implications
and endogenous effects. Pharmacogenomic J 2013;13:1–11.

SONG

ET AL.

29. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor
suppressor gene: important milestones at the various steps of
tumorigenesis. Genes Cancer. 2011;2:466–474.
30. Ben-Porath I, Weinberg RA. The signals and pathways activating
cellular senescence. Int J Biochem Cell Biol. 2005;37:961–976.
31. Boja ES, Rodriguez H. Proteogenomic convergence for understanding
cancer pathways and networks. Clin Proteomics. 2014;11:22.
32. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer
drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:
714–726.
33. Housman G, Byler S, Heerboth S, et al. Drug resistance in cancer: an
overview. Cancers. 2014;6:1769–1792.
34. Aksamitiene E, Kiyatkin A, Kholodenko BN. Cross-talk between
mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance.
Biochem Soc Trans. 2012;40:139–146.
35. Mitchell R, Kumar V, Abbas A, Aster J. Pocket companion to Robbins &
Cotran pathologic basis of disease. 8th ed. Philadelphia, United
Kingdom: Elsevier Health Science; 2011.
36. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation.
Cell. 2011;144:646–674.
37. Walsh JH, Karnes WE, Cuttitta F, Walker A. Autocrine growth factors
and solid tumor malignancy. West J Med. 1991;155:152–163.
38. Loeb KR, Loeb LA. Significance of multiple mutations in cancer.
Carcinogenesis. 2000;21:379–385.
39. Jang S, Atkins MB. Which drug, and when, for patients with BRAFmutant melanoma? Lancet. Oncol 2013;14:e60–e69.
40. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of
the PIK3CA gene in human cancers. Science. 2004;304:554.
41. Testa JR, Tsichlis PN. AKT signaling in normal and malignant cells.
Oncogene. 2005;24:7391–7393.
42. Gaglio D, Metallo CM, Gameiro PA, et al. Oncogenic K-Ras decouples
glucose and glutamine metabolism to support cancer cell growth. Mol
Syst Biol. 2011;7:523.
43. Yu M, Grady WM. Therapeutic targeting of the phosphatidylinositol 3kinase signaling pathway: novel targeted therapies and advances in
the treatment of colorectal cancer. Therap Adv Gastroenterol.
2012;5:319–337.
44. Gordon RR, Nelson PS. Cellular senescence and cancer chemotherapy
resistance. Drug Resist Updat. 2012;15:123–131.

|

101

45. Wei W, Herbig U, Wei S, Dutriaux A, Sedivy JM. Loss of
retinoblastoma but not p16 function allows bypass of replicative
senescence in human fibroblasts. EMBO Rep. 2003;4:1061–1066.
46. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent
cellular senescence in suppression of Pten-deficient tumorigenesis.
Nature. 2005;436:725–730.
47. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA.
Dose-dependent oncogene-induced senescence in vivo and its
evasion during mammary tumorigenesis. Nat Cell Biol. 2007;9:
493–505.
48. Cancer Genome Atlas Research N. Integrated genomic analyses of
ovarian carcinoma. Nature. 2011;474:609–615.
49. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations
account for a large proportion of ovarian carcinoma cases. Cancer.
2005;104:2807–2816.
50. Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin
of epithelial ovarian cancer--shifting the paradigm. Hum Pathol.
2011;42:918–931.
51. Campbell IG, Russell SE, Phillips WA. PIK3CA mutations in
ovarian cancer. Clin Cancer Res. 2005;11:7042–7043; author reply
7042–7043.

SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of the article.

How to cite this article: Song J-H, Lee C-J, An H-J, et al.
Magnolin targeting of ERK1/2 inhibits cell proliferation and
colony growth by induction of cellular senescence in ovarian
cancer cells. Molecular Carcinogenesis. 2019;58:88–101.
https://doi.org/10.1002/mc.22909

